🇺🇸 FDA
Pipeline program

Casirivimab and Imdevimab Antibody Cocktail

21-1223

Phase 1 small_molecule terminated

Quick answer

Casirivimab and Imdevimab Antibody Cocktail for COVID-19 is a Phase 1 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
COVID-19
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials